Steroid Treatment for Sickle Cell Pain Crisis
NCT00263562 · Status: TERMINATED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 18
Last updated 2020-07-07
Summary
The painful episode is the most common problem experienced by children with sickle cell disease. Although various treatments are available during painful episodes, the medication most commonly given for pain is a pain medication such as morphine. Fluids are also used. Even with these treatments, many children still have severe pain that is difficult to control. In addition to pain medications, there are other medications that may be useful. Methylprednisolone (solumedrol) and prednisone are a group of medications called steroids that may be helpful for painful episodes. These medications are known to lower the amount of inflammation (this means swelling, tenderness, and soreness) in the body. Because this medication may help with your pain, you are being asked to be a part of this study. These types of medications are used in other illnesses such as asthma, especially during times when the illness has gotten worse.
The main purpose of this study is to see if the methylprednisolone and prednisone will lower the amount of pain and the length of hospital stay.
In addition to the pain medication you will normally receive, you will be assigned to one of 2 groups: 1) the experimental group with the active form of the medicine, or 2) a comparison group without the active form of the medicine. In either group, you will still receive all of the treatments you would normally receive for a painful episode, including pain medicines and fluids. You and your doctors will not know what group you will be assigned.
If you decide to be a part of the study the following will happen:
For the first 5 days, you will be asked to: 1) describe your current pain (0=no pain to 10=a lot of pain), worst pain (0=no pain to 10=a lot of pain), least pain (0=no pain to 10=a lot of pain), and the amount of pain relief (0=no relief to 10=complete relief); 2) describe any signs or symptoms you feel, including filling out a pain scale form each day; 3) and take the medicines for 5 days, either at home or when in the hospital. Thirty days after the study, a study researcher will call and will ask questions about your pain, any painful episodes, and any medications you had. If you are discharged home sooner than 5 days after the start of the study, research staff will call you to ask you these questions, remind you to fill out your pain forms, and remind you to take your medicine. If you are discharged home, you will be given pain scales to fill out each day at home.
Conditions
- Sickle Cell Disease
- Vaso-occlusive Crisis
Interventions
- DRUG
-
Steroid arm
Day 1: Solumedrol 15 mg/kg (maximum 1 gram) Day 2: Prednisone 2mg/kg PO BID Day 3: Prednisone 2mg/kg PO daily Day 4: Prednisone 1mg/kg PO daily Day 5: Prednisone 1mg/kg PO daily
- OTHER
-
Placebo
Patients received normal saline in lieu of intravenously-administered methylprednisolone and placebo pills equal in number to the steroid pills received in the steroid arm
Sponsors & Collaborators
-
Baylor College of Medicine
lead OTHER
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- QUADRUPLE
- Model
- PARALLEL
Eligibility
- Min Age
- 8 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2005-12-01
- Primary Completion
- 2008-06-13
- Completion
- 2008-06-13
Countries
- United States
Study Locations
More Related Trials
-
Intranasal Fentanyl for Initial Treatment of a Vaso-occlusive Crisis
NCT01482091 ·Status: COMPLETED ·Phase: PHASE4
-
Oral Magnesium Pidolate, Hemoglobin SC Disease, MG Pidolate
NCT00040456 ·Status: TERMINATED ·Phase: PHASE2
-
Dexamethasone to Treat Acute Chest Syndrome in People With Sickle Cell Disease
NCT00530270 ·Status: TERMINATED ·Phase: PHASE3
-
Hydroxyurea to Prevent Brain Injury in Sickle Cell Disease
NCT01389024 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 1 Study of Zoledronic Acid in Sickle Cell Disease
NCT00639392 ·Status: WITHDRAWN ·Phase: PHASE1/PHASE2
-
Intravenous L-Citrulline for Vaso-occlusive Pain Episode in Sickle Cell Disease
NCT06635902 ·Status: RECRUITING ·Phase: PHASE2
-
MAST - Magnesium for Sickle Cell Acute Crisis in Children
NCT00313963 ·Status: COMPLETED ·Phase: PHASE3
-
Does IV Acetaminophen Reduce Opioid Requirement in Pediatric Patients With Acute Sickle Cell Crises?
NCT03541980 ·Status: COMPLETED ·Phase: PHASE4
-
Phase III Randomized Study of Poloxamer 188 for Vaso-Occlusive Crisis of Sickle Cell Disease
NCT00004408 ·Status: COMPLETED ·Phase: PHASE3
-
A Study of the Efficacy and Safety of ICA-17043 (With or Without Hydroxyurea) in Patients With Sickle Cell Anemia.
NCT00040677 ·Status: COMPLETED ·Phase: PHASE2
-
Preliminary Feasibility and Efficacy of Behavioral Intervention to Reduce Pain-Related Disability in Pediatric SCD
NCT04388241 ·Status: COMPLETED ·Phase: NA
-
Risk-based Therapy for Sickle Cell Anemia: A Feasibility Study
NCT02090296 ·Status: WITHDRAWN ·Phase: PHASE2
-
The Use of Warmed Saline in Vaso-occlusive Episodes
NCT02316366 ·Status: COMPLETED ·Phase: NA
-
Myeloablative Conditioning, Prophylactic Defibrotide and Haplo AlloSCT for Patients With Sickle Cell Disease
NCT02675959 ·Status: RECRUITING ·Phase: PHASE2
-
Use of Hydroxyurea and Magnesium Pidolate for Treatment of Sickle Cell Disease
NCT00143572 ·Status: COMPLETED ·Phase: PHASE1
-
Intranasal Fentanyl Versus Intravenous Morphine in the Treatment of Severe Painful Sickle Cell Crises in Children
NCT03682211 ·Status: COMPLETED ·Phase: PHASE4
-
Efficacy and Safety of Tocilizumab for Acute Chest Syndrome Treatment in Patients With Sickle Cell Disease
NCT06818266 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3
-
Hydroxyurea and Magnesium Pidolate to Treat People With Hemoglobin Sickle Cell Disease
NCT00532883 ·Status: TERMINATED ·Phase: PHASE2
-
A Phase 1 Study of Continuous Intravenous L-citrulline During Sickle Cell Pain Crisis or Acute Chest Syndrome
NCT02697240 ·Status: COMPLETED ·Phase: PHASE1
-
Inhaled Mometasone to Reduce Painful Episodes in Patients With Sickle Cell Disease
NCT02061202 ·Status: COMPLETED ·Phase: PHASE2
-
Novel Dose Escalation to Predict Treatment With Hydroxyurea
NCT02042222 ·Status: COMPLETED ·Phase: EARLY_PHASE1
-
Ketamine Infusion for Sickle Cell Pain Crisis
NCT04005209 ·Status: WITHDRAWN ·Phase: PHASE4
-
Voxelotor Brain Oxygenation and Neurocognitive Study
NCT05228821 ·Status: WITHDRAWN ·Phase: PHASE4
-
Abciximab (ReoPro) as a Therapeutic Intervention for Sickle Cell Vaso-Occlusive Pain Crisis
NCT01932554 ·Status: WITHDRAWN ·Phase: PHASE2
-
Ketorolac for Acute Vaso-Occlusive Crisis in Pediatric Sickle Cell Disease
NCT06579703 ·Status: NOT_YET_RECRUITING ·Phase: PHASE4